UNITÉ DE FABRICATION DES MÉDICAMENTS S.A |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.17 TND | -0.14% |
|
-0.69% | -4.14% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company is one of the best yield companies with high dividend expectations.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -4.14% | 73.1M | - | ||
| +21.85% | 546B | B | ||
| -4.77% | 359B | C+ | ||
| +16.97% | 323B | B- | ||
| +5.69% | 290B | C+ | ||
| +13.68% | 234B | B+ | ||
| +3.65% | 198B | B- | ||
| -11.12% | 194B | A+ | ||
| +8.08% | 167B | C+ | ||
| -3.40% | 157B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- UMED Stock
- Ratings Unité de Fabrication des Médicaments S.A
